Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD
Abstract Background Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph-negative BCP-ALL) accounts for a significant portion of adult cases. Blinatumomab, a bispecific T-cell engager, has shown efficacy in relapsed or refractory BCP-ALL, but its role in induction therapy with re...
Shranjeno v:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer
2025-02-01
|
| Serija: | Discover Oncology |
| Teme: | |
| Online dostop: | https://doi.org/10.1007/s12672-025-01968-8 |
| Oznake: |
Brez oznak, prvi označite!
|
